ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)

Aug 08, 2016, 01:30 ET from ThromboGenics

LEUVEN, Belgium, August 8, 2016 /PRNewswire/ --

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the results from its 2 Year OASIS Phase IIIb study with JETREA® (ocriplasmin) have been published in the renowned AAO Journal Ophthalmology.

Ophthalmology reviewed the OASIS study which was a Phase IIIb randomized, sham controlled, double masked study that followed up patients for 24 months post injection. The study was designed to provide long term controlled efficacy and safety data for JETREA® in patients being treated for symptomatic vitreomacular adhesion (sVMA). The study included 24 months follow up data, the longest period patients have been studied post treatment with this novel medicine.

In its overall conclusion, Ophthalmology confirms 'the OASIS trial demonstrates the long-term efficacy and safety of ocriplasmin, providing improved resolution of symptomatic VMA compared with previous phase 3 trials with no additional safety signals identified'.

The article 'Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial' can be consulted online here.

Dr Patrik De Haes, CEO of ThromboGenics, said: "We are pleased that the positive results from this Phase IIIb randomized, controlled trial have now been published in the prestigious AAO Journal Ophthalmology. We are confident that the OASIS data will provide very helpful guidance to the global retina community in their assessment of JETREA® as an effective and safe treatment option for an important group of patients with symptomatic VMA."

The OASIS study results, including the sub-study read out, will be the subject of various presentations delivered at upcoming US and global retina specialists educational meetings, such as next week's 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in San Francisco, and the Annual Meeting of the American Academy of Ophthalmology (AAO) from the 15thto 18th October in Chicago.

About ThromboGenics  

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease.

ThromboGenics pioneered the new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is approved for treatment of vitreomacular traction in 54 countries worldwide.

The company's pipeline of disease modifying drug candidates (THR-409, THR-317, THR-149, THR-687) targets all key segments of the diabetic eye disease market: diabetic retinopathy (DR, NPDR, PDR) and/or diabetic macular edema (DME).

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at http://www.thrombogenics.com

Important information about forward-looking statements 

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. 

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction.  No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws. 

For further information please contact:

ThromboGenics 

Wouter Piepers, Global Head of Corporate Communications & Investor Relations
Tel: +32-16-75-13-10 / +32-478-33-56-32
wouter.piepers@thrombogenics.com

Citigate Dewe Rogerson 

David Dible/ Sylvie Berrebi
Tel: +44-20-7282-1052  
sylvie.berrebi@citigatedr.co.uk

SOURCE ThromboGenics